Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.

ABSTRACT:

SUBMITTER: Northend M 

PROVIDER: S-EPMC9092410 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature